Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zistdaru Danesh rituximab versus MabThera in R-CHOP for DLBCL
IRCT20211218053442N3Phase 3Recruiting
- Sponsor
- Zistdaru Danesh
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Zistdaru Danesh. Started Jan 2026; status: recruiting.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on IRCT20211218053442N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211218053442N3.